Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.39 USD | -5.53% | +1.70% | -63.95% |
16/04 | Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02/04 | Appili Therapeutics To be Acquired by Aditxt, Inc. | MT |
Sales 2022 | 0.93 77.89 | Sales 2023 | 0.65 53.82 | Capitalization | 8.28M 691M |
---|---|---|---|---|---|
Net income 2022 | -27M -2.25B | Net income 2023 | -32M -2.67B | EV / Sales 2022 | 59,68,543 x |
Net Debt 2022 | 613K 51.15M | Net Debt 2023 | 18.12M 1.51B | EV / Sales 2023 | 4,09,20,944 x |
P/E ratio 2022 |
-0.08
x | P/E ratio 2023 |
-0.06
x | Employees | 47 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.51% |
1 day | -5.53% | ||
1 week | +1.70% | ||
Current month | -29.71% | ||
1 month | -29.71% | ||
3 months | -38.87% | ||
6 months | -66.53% | ||
Current year | -63.95% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 61 | 28/17/28 | |
Amro Albanna
CEO | Chief Executive Officer | 54 | 28/17/28 |
Thomas Farley
DFI | Director of Finance/CFO | 51 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Runge
BRD | Director/Board Member | 67 | 10/20/10 |
Amro Albanna
CEO | Chief Executive Officer | 54 | 28/17/28 |
Founder | 61 | 28/17/28 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 2.39 | -5.53% | 65,777 |
25/24/25 | 2.53 | +6.75% | 181,004 |
24/24/24 | 2.37 | +4.41% | 28,051 |
23/24/23 | 2.27 | +2.25% | 26,841 |
22/24/22 | 2.22 | -5.53% | 62,239 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-63.95% | 3.98M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.73% | 22.15B | |
-17.37% | 21.02B | |
-8.96% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ADTX Stock